menu
    • menu
    [{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal ","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Infantis","moa":"Bacteria microbiome","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal ","highestDevelopmentStatusID":"1","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal "},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"6","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Preclinical","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich","highestDevelopmentStatusID":"4","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Bevacizumab-IRDye800CW","moa":"VEGF receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"8","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Medigene"}]

    Find Clinical Drug Pipeline Developments & Deals by Helmholtz Zentrum München

    Menu

    Helmholtz Zentrum München

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITM-31

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Isotope Technologies Munich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ITM and Helmholtz Doses First Patient in Phase I Glioblastoma Investigator-Initiated Trial

                            Details : ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment, which is currently being evaluated for the treatment of glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2024

                            Lead Product(s) : ITM-31

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Isotope Technologies Munich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Medigene

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medigene Acquires Worldwide, Exclusive License Of CD40L-CD28 Costimulatory Switch Receptor

                            Details : Under the agreement, Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Medigene

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITM-31

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment o...

                            Details : Under the terms of the license agreement, ITM will hold exclusive rights to the compound ITM-31 as well as the rights to related patents and know-how for the manufacturing and use of ITM-31.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : ITM-31

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium Infantis

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

                            Details : B. Infantis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 24, 2021

                            Lead Product(s) : Bifidobacterium Infantis

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helmholtz Zentrum München

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab-IRDye800CW

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : University Medical Center Groningen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Detection of Early Esophageal Cancer by NIR-FME.

                            Details : Bevacizumab-IRDye800CW is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Barrett Esophagus.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 15, 2019

                            Lead Product(s) : Bevacizumab-IRDye800CW

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : University Medical Center Groningen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth